Product logins

Find logins to all Clarivate products below.


: Regulation

Here you will find relevant articles and insight into all Clarivate related products and news.

Blog December 18, 2018
Orphan drug access varies across multiple markets
Cortellis Cortellis Competitive Intelligence Cortellis Regulatory Intelligence
Blog November 20, 2018
U.S. enhances malaria-fighting toolkit
CDC Cortellis Cortellis Regulatory Intelligence
Blog September 26, 2018
Generics companies, responding to tough times, steer towards higher-risk portfolio strategies
Competitive Intelligence Cortellis CPhI
Blog September 13, 2018
FDA actions to improve prescription drug labeling for pregnancy
Clinical Trials Cortellis Cortellis Clinical Trials Intelligence
Blog July 26, 2018
Improvements charted in reduction of time to new drug approvals at key regulatory authorities
Centre for Innovation in Regulatory Science CIRS Cortellis
Blog July 17, 2018
China emerging as global reg leader
CFDA CNDA Cortellis
Blog June 26, 2018
Regulatory considerations, strategy and best practices for choosing a quality CMO
CDMO cGMP CMO
Blog June 12, 2018
FDA focuses on drug supply chain security
Cortellis Cortellis Regulatory Intelligence drug supply chain

Regulation

Blog December 18, 2018
Orphan drug access varies across multiple markets
Blog November 20, 2018
U.S. enhances malaria-fighting toolkit
Blog September 26, 2018
Generics companies, responding to tough times, steer towards higher-risk portfolio strategies
Blog September 13, 2018
FDA actions to improve prescription drug labeling for pregnancy
Blog July 26, 2018
Improvements charted in reduction of time to new drug approvals at key regulatory authorities
Blog July 17, 2018
China emerging as global reg leader
Blog June 26, 2018
Regulatory considerations, strategy and best practices for choosing a quality CMO
Blog June 12, 2018
FDA focuses on drug supply chain security
Blog June 5, 2018
FDA efficacy recommendations vary for hypogonadotropic hypogonadism drugs
Blog March 6, 2018
Generics industry sets record for U.S. approvals, has ‘nothing to apologize for’